Cryo-Cell's Losses Widen Amidst Revenue Dip; Secures New Credit Line

TL;DR

**CCEL is bleeding cash and needs this new loan to stay afloat; proceed with extreme caution.**

AI Summary

CRYO CELL INTERNATIONAL INC (CCEL) reported a net loss of $1.1 million for the three months ended May 31, 2025, a significant increase from the $0.3 million net loss in the prior-year period. Revenue for the three months ended May 31, 2025, decreased by 1.8% to $7.7 million, down from $7.8 million in the same period last year. For the six months ended May 31, 2025, the company's net loss widened to $2.0 million, compared to a net loss of $0.6 million in the corresponding period of 2024. Total revenue for the six months ended May 31, 2025, also saw a slight decline of 0.6% to $15.4 million from $15.5 million. The company's cash and cash equivalents decreased to $1.9 million as of May 31, 2025, from $2.9 million at November 30, 2024. A key business change includes the subsequent event of entering into a new credit agreement with Susser Bank on July 15, 2025, providing a $10.0 million revolving credit facility and a $5.0 million term loan, replacing the previous Susser Bank credit agreement. Risks include the reliance on the new credit facility and the ongoing net losses, which could impact future liquidity and operations. The strategic outlook involves leveraging the new credit facility to support operations and potentially fund growth initiatives, though the immediate focus appears to be on managing liquidity amidst declining revenue and increasing losses.

Why It Matters

Cryo-Cell's widening net losses and declining revenue signal potential operational challenges, impacting investor confidence and future growth prospects. The new $15.0 million credit facility from Susser Bank, while providing immediate liquidity, also increases the company's debt burden, which could affect its competitive position against larger, more financially stable stem cell banking rivals. Employees might face uncertainty if financial performance continues to deteriorate, and customers could be concerned about the long-term viability of their stored biological assets. The broader market will watch to see if this new financing can stabilize the company and reverse its negative trends in the highly competitive biotech and healthcare services sector.

Risk Assessment

Risk Level: high — The company reported a net loss of $1.1 million for the three months ended May 31, 2025, and a $2.0 million net loss for the six months, indicating persistent unprofitability. Cash and cash equivalents decreased from $2.9 million at November 30, 2024, to $1.9 million at May 31, 2025, highlighting a deteriorating liquidity position that necessitated a new $15.0 million credit facility from Susser Bank.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to CCEL given the widening losses and declining cash reserves. Monitor the company's ability to effectively utilize the new Susser Bank credit facility to reverse negative financial trends and achieve profitability.

Financial Highlights

debt To Equity

N/A

revenue

$15.4M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$2.0M

eps

N/A

gross Margin

N/A

cash Position

$1.9M

revenue Growth

-0.6%

Revenue Breakdown

Key Numbers

• $1.1M — Net Loss (Q2 2025) (Increased from $0.3M in Q2 2024, indicating widening unprofitability.)
• $7.7M — Revenue (Q2 2025) (Decreased by 1.8% from $7.8M in Q2 2024, showing revenue decline.)
• $2.0M — Net Loss (YTD 2025) (Widened from $0.6M in YTD 2024, reflecting sustained losses.)
• $15.4M — Revenue (YTD 2025) (Slightly decreased by 0.6% from $15.5M in YTD 2024.)
• $1.9M — Cash & Equivalents (Decreased from $2.9M at Nov 30, 2024, highlighting liquidity concerns.)
• $15.0M — New Credit Facility (Secured from Susser Bank on July 15, 2025, crucial for liquidity.)
• 1.8% — Q2 Revenue Decrease (Percentage decline in revenue for the three months ended May 31, 2025.)
• 0.6% — YTD Revenue Decrease (Percentage decline in revenue for the six months ended May 31, 2025.)

Key Players & Entities

• CRYO CELL INTERNATIONAL INC (company) — filer of the 10-Q
• Susser Bank (company) — lender for the new credit agreement
• $1.1 million (dollar_amount) — net loss for three months ended May 31, 2025
• $0.3 million (dollar_amount) — net loss for three months ended May 31, 2024
• $7.7 million (dollar_amount) — revenue for three months ended May 31, 2025
• $7.8 million (dollar_amount) — revenue for three months ended May 31, 2024
• $2.0 million (dollar_amount) — net loss for six months ended May 31, 2025
• $0.6 million (dollar_amount) — net loss for six months ended May 31, 2024
• $1.9 million (dollar_amount) — cash and cash equivalents as of May 31, 2025
• $15.0 million (dollar_amount) — total amount of new credit facility from Susser Bank

FAQ

Risk Factors

• Deteriorating Profitability and Liquidity [high — financial]: The company reported a net loss of $1.1 million for Q2 2025, a significant increase from $0.3 million in Q2 2024. Year-to-date net loss widened to $2.0 million from $0.6 million. Cash and cash equivalents decreased to $1.9 million as of May 31, 2025, from $2.9 million at November 30, 2024, indicating a strain on liquidity.
• Reliance on New Credit Facility [high — financial]: A new credit agreement was entered into on July 15, 2025, providing a $10.0 million revolving credit facility and a $5.0 million term loan. This facility is crucial for supporting operations and managing liquidity, but its availability and terms represent a significant ongoing risk.
• Declining Revenue Trends [medium — operational]: Revenue has shown a downward trend, with a 1.8% decrease in Q2 2025 and a 0.6% decrease year-to-date. This decline, if it persists, could further pressure profitability and the company's ability to service its debt and fund operations.

Industry Context

CRYO CELL INTERNATIONAL INC operates in the health and allied services sector, specifically focusing on cord blood and stem cell banking. This industry is characterized by long-term storage contracts and requires significant investment in technology and compliance. Competition may come from other established players and emerging biotechnologies. Trends include advancements in stem cell therapies and increasing awareness among expectant parents.

Regulatory Implications

As a health services company, CRYO CELL INTERNATIONAL INC is subject to various healthcare regulations, including those related to laboratory practices, data privacy (e.g., HIPAA if applicable), and potentially FDA oversight depending on the services offered. Compliance with these regulations is critical to maintaining operational licenses and public trust.

What Investors Should Do

1. Monitor cash burn rate and liquidity runway.
2. Evaluate the effectiveness of the new credit facility.
3. Analyze revenue drivers and potential for turnaround.

Key Dates

• 2025-05-31: End of Second Quarter Fiscal Year 2025 — Reporting period for the 10-Q filing, showing increased net loss and decreased revenue compared to the prior year.
• 2025-07-15: New Credit Agreement with Susser Bank — Secured a $10.0 million revolving credit facility and a $5.0 million term loan, replacing the previous agreement and providing critical liquidity support.
• 2024-11-30: End of Fiscal Year 2024 — Prior period for cash and equivalents comparison, showing a decrease from $2.9 million to $1.9 million by May 31, 2025.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the source of the financial data and analysis presented.)

Cash and Cash Equivalents

Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Indicates the company's immediate liquidity, which has decreased, raising concerns.)

Net Loss

The total expenses incurred by a company exceed its total revenues over a specific period. (The company is experiencing widening net losses, impacting its financial health.)

Revolving Credit Facility

A type of credit line that allows a company to borrow, repay, and re-borrow funds up to a certain limit over a specified period. (The new $10.0 million facility is a key component of the company's liquidity strategy.)

Term Loan

A loan from a bank or other lender for a specific amount that has a specified repayment schedule and a fixed or floating interest rate. (The $5.0 million term loan is part of the new financing package.)

Subsequent Event

A significant event that occurs after the balance sheet date but before the financial statements are issued. (The new credit agreement is a material subsequent event impacting the company's financial position.)

Year-Over-Year Comparison

Compared to the previous fiscal year, CRYO CELL INTERNATIONAL INC has experienced a decline in both revenue and profitability. For the six months ended May 31, 2025, revenue decreased by 0.6% to $15.4 million, and the net loss widened significantly to $2.0 million from $0.6 million in the prior year. Cash reserves have also diminished, falling from $2.9 million to $1.9 million. A key development is the subsequent event of securing a new, larger credit facility, which addresses immediate liquidity concerns but highlights the ongoing financial challenges.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on July 15, 2025 regarding CRYO CELL INTERNATIONAL INC (CCEL).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR